200 related articles for article (PubMed ID: 19126664)
1. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease.
Wright JW; Harding JW
J Renin Angiotensin Aldosterone Syst; 2008 Dec; 9(4):226-37. PubMed ID: 19126664
[TBL] [Abstract][Full Text] [Related]
2. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
[TBL] [Abstract][Full Text] [Related]
3. The brain RAS and Alzheimer's disease.
Wright JW; Harding JW
Exp Neurol; 2010 Jun; 223(2):326-33. PubMed ID: 19782074
[TBL] [Abstract][Full Text] [Related]
4. Norleucine1-Angiotensin IV alleviates mecamylamine-induced spatial memory deficits.
Olson ML; Olson EA; Qualls JH; Stratton JJ; Harding JW; Wright JW
Peptides; 2004 Feb; 25(2):233-41. PubMed ID: 15063004
[TBL] [Abstract][Full Text] [Related]
5. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
Wright JW; Kawas LH; Harding JW
Prog Neurobiol; 2015 Feb; 125():26-46. PubMed ID: 25455861
[TBL] [Abstract][Full Text] [Related]
6. Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders.
Hallberg M
Drug News Perspect; 2009 Apr; 22(3):133-9. PubMed ID: 19440555
[TBL] [Abstract][Full Text] [Related]
7. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory.
Wright JW; Harding JW
Prog Neurobiol; 2004 Mar; 72(4):263-93. PubMed ID: 15142685
[TBL] [Abstract][Full Text] [Related]
8. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia.
Ciobica A; Bild W; Hritcu L; Haulica I
Acta Neurol Belg; 2009 Sep; 109(3):171-80. PubMed ID: 19902810
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.
Domeney AM
J Psychiatry Neurosci; 1994 Jan; 19(1):46-50. PubMed ID: 8148365
[TBL] [Abstract][Full Text] [Related]
10. Potential for antihypertensive treatment with an AT(1)-receptor blocker to reduce dementia in the elderly.
Trenkwalder P
J Hum Hypertens; 2002 Aug; 16 Suppl 3():S71-5. PubMed ID: 12140732
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin II receptor blockers on dementia.
Mogi M; Horiuchi M
Hypertens Res; 2009 Sep; 32(9):738-40. PubMed ID: 19727113
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin and Alzheimer's disease: therapeutic prospects.
Gard PR; Rusted JM
Expert Rev Neurother; 2004 Jan; 4(1):87-96. PubMed ID: 15853619
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.
Kidd PM
Altern Med Rev; 2008 Jun; 13(2):85-115. PubMed ID: 18590347
[TBL] [Abstract][Full Text] [Related]
14. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
Terry AV; Buccafusco JJ; Wilson C
Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
[TBL] [Abstract][Full Text] [Related]
15. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
Geldenhuys WJ; Van der Schyf CJ
Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
[TBL] [Abstract][Full Text] [Related]
16. The role of the AT4 and cholinergic systems in the Nucleus Basalis Magnocellularis (NBM): effects on spatial memory.
Wilson WL; Munn C; Ross RC; Harding JW; Wright JW
Brain Res; 2009 May; 1272():25-31. PubMed ID: 19328191
[TBL] [Abstract][Full Text] [Related]
17. Do angiotensin receptor blockers prevent Alzheimer's disease?
Hajjar I; Rodgers K
Curr Opin Cardiol; 2013 Jul; 28(4):417-25. PubMed ID: 23703253
[TBL] [Abstract][Full Text] [Related]
18. Biochemical models for cognition enhancers.
Costall B; Barnes JM; Hamon M; Müller WE; Briley M
Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():85-8; discussion 89. PubMed ID: 2186420
[TBL] [Abstract][Full Text] [Related]
19. [Usage of drugs with potential adverse effects on cognition in a memory-clinic].
Weih M; Scholz S; Reiss K; Alexopoulos P; Degirmenci U; Richter-Schmidinger T; Kornhuber J
Fortschr Neurol Psychiatr; 2009 Sep; 77(9):523-7. PubMed ID: 19644785
[TBL] [Abstract][Full Text] [Related]
20. Oxygen treatment triggers cognitive impairment in Alzheimer's transgenic mice.
Arendash GW; Cox AA; Mori T; Cracchiolo JR; Hensley KL; Roberts LJ
Neuroreport; 2009 Aug; 20(12):1087-92. PubMed ID: 19543132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
